STING1 and breast cancer: To the contrary, emerging evidence from multiple tumour settings, including carcinogen-induced skin cancer [34], Lewis lung carcinoma [35], chromosomally unstable triple-negative breast cancer (TNBC) [36] and metastatic lung and breast cancer models [13, 37] has now begun to reveal a role for cGAS–STING activity as a driver of tumour progression.